An Open-Label, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
An Open-label, Phase 2 study of efficacy and tolerability of ABT-869 in advanced
hepatocellular carcinoma (HCC)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-Free Rate
Week 16
No
Justin Ricker, MD
Study Director
AbbVie
United States: Food and Drug Administration
M06-879
NCT00517920
September 2007
June 2012
Name | Location |
---|---|
Site Reference ID/Investigator# 7726 | Philadelphia, Pennsylvania 19107 |